LKLidia Kozlovskaya

Lidia Kozlovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lidia Kozlovskaya has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Direct-acting antiviral agents for HCV-associated cryoglobulinemic vasculitis. Does viral eradication always lead to the achievement of complete clinical and immunological responses?

    by S.YU. Milovanova, L.V. Kozlovskaya (Lysenko), L.YU. Milovanova, D.T. Abdurakhmanov, M.V. Taranova

    Direct-acting antiviral agents (DAAs) are highly effective in treating HCV-associated cryoglobulinemic vasculitis (HCV-CV), achieving a sustained virological response (SVR) in 95—100% of patients. However, some patients still show immunological markers and sporadic vasculitis symptoms post-eradication. Objective. To evaluate clinical and immunological responses in patients with HCV-CV compared to patients with «asymptomatic» HCV-associated cryoglobulinemia (HCV-CG) after a course of DAA therapy during prolonged observation. Material and Methods. The study included 45 patients: 23 with HCV-CV and 22 with HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological and virological data were assessed before treatment, at 12 and 48 weeks after treatment. Results. An SVR was achieved in 100% of patients after the DAA course. In patients with HCV-CV, an immunological response was observed in 56.5% by week 12 (SVR12) and 73.9% by week 48 (SVR48). Six patients (26.1%) did not achieve an immunological response by SVR48. The frequency of complete and partial clinical response by SVR12 among these patients was 65.2%, and by SVR48 — 78.3%. In 5 patients (21.7%) manifestations of HCV-CV persisted and/or relapsed. In patients with HCV-CG, the rate of complete and partial immunological response after DAA therapy was 77.3% at SVR12 and 86.3% at SVR48. Three patients showed no response, characterized by trace-level cryoglobulinemia. Conclusion. Most HCV-CV patients reach remission with DAA treatment. However, 20% of patients continue to exhibit/recurrent CV manifestations after treatment. Based on these observations, patients with HCV-CV, especially those with severe initial skin and kidney involvement, require long-term monitoring after achieving SVR.

  • Therapy with direct antiviral drugs in patients with HCVassociated cryoglobulinemic vasculitis – is it always possible to achieve complete clinical and immunological responses after the virus eradication?

    by S. Yu. Milovanova, L. V. Kozlovskaya (Lysenko), L. Yu. Milovanova, D. T. Abdurakhmanov, M. V. Taranova, A. V. Volkov

    Background. The use of direct acting antiviral drugs (DAАs) leads to the achievement of a stable virological response (SVR) in 95–100 % of patients with HCV-associated cryoglobulinemic vasculitis (HCV-CV). However, in some patients, despite the eradication of the virus, clinical and immunological markers of vasculitis still remain.The aim: to evaluate clinical and immunological responses in patients with HCV-CV in comparison with patients with "asymptomatic" HCV- associated cryoglobulinemia (HCV- СG) after achieving SVR with the help of DAАs with long-term dynamic observation (12 months).Patients and Methods: The study included 45 patients: 23 with HCV-CV and 22 with "asymptomatic" HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological, virological data were evaluated: before treatment, 12 weeks (3 months) and 48 weeks (12 months) after the end of treatment.Results: After a course of DAAs, SVR was diagnosed in all 45 (100 % of patients). In patients with HCV-CV, an immunological response (complete and partial) was observed by week 12 (SVR12) – in 56.5 % and by week 48 (SVR48) – in 73.9 % patients. In 6 patients (26.1 %), the immunological response was not achieved by SVR48. The rate of complete and partial clinical response 12 weeks after the end of treatment at the SVR12 period in patients with HCV-CV was 65.2 %, to the time of SVR48 amounted to 78.3 % patients. In 5 (21.7 %) individual manifestations of CV persisted and/or relapsed. In patients with HCV-CG, the frequency of complete and partial immunological responses after DAAs therapy was 77.3 % – by SVR12 and 86.3 % – by SVR48, respectively. No response was observed in 3 patients and it was characterized by trace-level of cryoglobulinemia.Conclusion: In most patients with HCV-CV eradication of HCV with help of DAAs leads to the achievement of clinical and immunological remission of the disease. However, in 20 % of patients manifestations of HCV-CV persist / recur immediately after the end of treatment or later relapses are observed. Based on these observations, patients with HCV-CV, especially those with severe underlying skin and kidney disease, are required long-term monitoring after SVR is achieved.

  • Cryoglobulinemic vasculitis associated with HCV infection: still a problem?

    by S. Yu. Milovanova, L. V. Lysenko (Kozlovskaya), L. Yu. Milovanova, Дж. Т. Абдурахманов, M. V. Taranova, A. V. Volkov

    The review presents the main data on the problem of cryoglobulinemic vasculitis associated with HCV infection. The options for the course are considered, and modern diagnostic criteria, the choice of tactics, and the effectiveness of various treatment regimens are presented. The use of modern antiviral drugs makes it possible to achieve the eradication of the virus in 95 % of patients. However, in some patients, clinical and immunologic markers of vasculitis persist despite viral clearance. The article discusses the concept that the persistence of B-cell clones after achieving a sustained virological response may underlie the pathogenesis of HCV-independent CV reactivation.


  • The critical role of chronic kidney disease in the progression of AL-amyloid cardiopathy

    by Anna Rameeva, Ksenia Vedanova, Vilen Rameev, Ayten Safarova, Irina Bobkova, Lidia Kozlovskaya, Sergey Moiseev

    (2019). The critical role of chronic kidney disease in the progression of AL-amyloid cardiopathy. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 109-110.

  • Open Access

    Low aquaporin-2 excretion in the nephrotic syndrome: an escape from the vasopressin regulating effect

    by Mikhail Brovko, Lidia Kozlovskaya, Andrey Pulin, Sergey Moiseev, Viсtoria Sholomova, Dmitry Shchekochikhin, Daria Gognieva, Ludmila Milovanova, Victor Fomin

    Purpose: Experimental studies suggest that the nephrotic syndrome is associated with “vasopressin escape”, characterized by low aquaporin-2 (AQP2) expression in the collecting duct despite high vasopressin secretion. We investigated this phenomenon in patients with the nephrotic syndrome. Patients and methods: We recruited 47 patients with proteinuric kidney disease who were distributed into the following four groups: 1) nephrotic syndrome with kidney dysfunction (n=10); 2) nephrotic syndrome with normal kidney function (n=16); 3) partial remission of nephrotic syndrome (n=10); and 4) minimal proteinuria (n=11). Nine healthy volunteers comprised a control group. Serum copeptin level (as a marker of vasopressin secretion) and urinary AQP2 were measured using ELISA. Results: Nephrotic syndrome was associated with a significant increase in serum copeptin levels compared with those in the other groups (all PPPP=0.005). Conclusion: Our clinical study was the first to demonstrate low AQP2 excretion in nephrotic syndrome that may indicate an escape from the vasopressin regulating effect.


  • Open Access

    Evaluation of cardiovascular risks with the use of morphogenetic Klotho protein in patients with chronic renal disease

    by N. A. Mukhin, L. Yu. Milovanova, V. V. Fomin, L. V. Kozlovskaya, M. V. Taranova, T. V. Androsova, A. A. Borisov

    Of the study was to explore the Klotho protein significance in patients with different stages of chronic kidney disease (CKD) and to assess the influence of antihypertensive therapy on Klotho protein serum levels. 130 patients with stage 5 CKD1 were included in the study. Serum PTH, calcium and phosphorus were measured. ELISA was used to determine serum soluble alpha Klotho. Blood pressure including brachial and central (aortic) pressure was measured in all patients together with pulse wave velocity (using a «Sfigmokor» device); in addition, echocardiography (EchoCG), and X-ray examination of the abdominal aorta by Kauppila method were performed. The dynamic study of serum Klotho level showed that it changes with decreasing glomerular filtration rate faster than a rise in phosphate and PTH levels starting from stage 3A of CKD. The two later variables increased at stages 4-5.According to the ROC analysis, the values of serum Klotho below 387 pg /ml suggested enhanced risk of myocardial calcification with 80% sensitivity and 76% specificity. In addition, the highest Klotho serum levels were observed in patients whose target BP values were achieved with angiotensin receptor blockers (ARB) compared to those who used other drugs [р<0,01] or failed to reached target BP levels [p=0,008]. The study showed the possibility of practical use of Klotho protein as an early diagnostic marker of cardiovascular risk. Reduced serum Klotho was less pronounced in patients who used ARB for correction of high blood pressure. Normal Klotho protein levels in serum have been associated with a lower frequency of heart and vessels calcification in CKD patients.


  • Open Access

    Risk factors for anemia in the early stages of chronic kidney disease

    by Yu. S. Milovanov, L. V. Kozlovskaya, L. Yu. Milovanova, M. M. Markina, V. V. Kozlov, M. V. Taranova, V. V. Fomin

    To identify the early markers of anemia in chronic kidney disease (CKD) in patients with chronic glomerulonephritis (CGN) and glomerulonephritis (GN) in systemic diseases. Seventy-nine patients with some male preponderance who were aged 21 to 65 years (45.3±11.1 years) and had CKD (CGN and GN) in systemic diseases (systemic lupus erythematosus and Wegener's granulomatosis) in the early stages (Stages I-II) of CKD were examined. GN was diagnosed by a lifetime renal biopsy. Systemic diseases were diagnosed according to the criteria for each nosological entity. The stages of CKD were defined according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria; the glomerular filtration rate (GFR) was calculated using the CKD EPI equation (2012). According to the presence or absence of anemia, all the patients included in the study were divided into 2 groups: 1) 43 (54.4%) anemic patients; 2) 36 (45.6%) non-anemic patients (a control group). In addition to general clinical examination adopted for a nephrology department, special studies, such as determination of the serum levels of hepcidin, interferon-γ (IFN-γ), soluble Klotho protein (s-Klotho), as well as iron, ferritin, and transferrin saturation (TSAT) ratio, were performed to solve the set tasks. Forty-three anemic patients who had a hemoglobin level of 110 (100; 119) g/l and 36 control patients who had the similar values were noted to have statistically significantly (p 0.001), was associated with the development of anemia. Moreover, the hemoglobin level of<120 g/ l was found to have an independent impact on the risk of reducing serum s-Klotho production. In Stage I-II CKD patients with CGN and GN in the presence of systemic diseases, elevated serum hepcidin levels should be regarded as a predictor for anemia of chronic disease (ACD). Herewith, the decrease in hemoglobin levels <120 g/l is associated with the reduced production of the nephroprotective factor s-Klotho. The treatment of ACD for Stages I-II CKD should encompass intravenous administration of iron in order to increase its content and availability for erythropoiesis.


  • Open Access

    Pathophysiology and clinical studies in CKD 1-5.

    by Magdy El Sharkawy, Kadry Elsaeed, Mostafa Kamel, Ahmed Aziz, Carlos Del Pozo, Anja Balk, Juan Castello-Banyuls, Daniela Navarro, Berbel Pere, Clara C. Faura, et al.

    INTRODUCTION AND AIMS: Gastrointestinal (GI) symptoms are common in patients with chronic renal failure (CRF), but the pathogenesis of these symptoms is unclear. Abnormal gastric motility disorders and esophageal motor dysfunctions are commonly described in uremic patients. The gastrointestinal disorders possibly affect function and structure of the gastrointestinal tract and negatively impact on the nutritional status of the patients causing malnutrition which is a major problem with ESRD.